Loading
The single-arm study behind the first c-Met-directed antibody-drug conjugate approval in lung cancer: tumours shrank in about a third of patients whose cancers carried high c-Met protein, with eye and nerve side effects to watch.
LUMINOSITY, trial NCT03539536 sponsored by AbbVie and published in the Journal of Clinical Oncology in 2024, gave telisotuzumab vedotin to previously treated patients with non-squamous, EGFR wild-type non-small-cell lung cancer whose tumours overexpressed c-Met protein on immunohistochemistry. The objective response rate was 28.6% overall, 34.6% in the c-Met high group and 22.9% in the intermediate group, with peripheral sensory neuropathy, peripheral oedema and keratitis among the notable side effects. The c-Met high results supported the 2025 US accelerated approval of Emrelis, the first c-Met-directed ADC in lung cancer; the confirmatory phase 3 trial TeliMET NSCLC-01 is ongoing.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
270 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective response rate (independent review)primary | Telisotuzumab vedotin, c-Met high | 78 | 34.6% | - | - | link |
| Telisotuzumab vedotin, c-Met intermediate | 83 | 22.9% |
A second publication from the LUMINOSITY trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
This is the paper Europe PMC returns for registry id NCT03539536 with the most citations, so it is the natural first reading for anyone following the LUMINOSITY trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
Shares Telisotuzumab vedotin, MET exon 14 and MET-amplified non-small-cell lung cancer, MET, AbbVie (incl. ImmunoGen, Capstan).
Shares Telisotuzumab vedotin, MET exon 14 and MET-amplified non-small-cell lung cancer, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC).
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, MET, Non-small-cell lung cancer.
Shares Telisotuzumab vedotin, MET exon 14 and MET-amplified non-small-cell lung cancer, Antibody-drug conjugate (ADC).
Shares Telisotuzumab vedotin, MET exon 14 and MET-amplified non-small-cell lung cancer, MET, Lung cancer (all types).
Shares Telisotuzumab vedotin, MET exon 14 and MET-amplified non-small-cell lung cancer, MET, Lung cancer (all types).
Shares Telisotuzumab vedotin, MET, Non-small-cell lung cancer.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Lung cancer (all types), Non-small-cell lung cancer.